RACHAEL FORTUNATO: Open Payments
NPI 1285279398 · PEMBROKE, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$631 in 48 payments from 9 companies in 2025. Trend: 2023 $1,312 · 2024 $1,168 · 2025 $631
Food & beverage: $631
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 32 | $322 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $63 |
| E.R. Squibb & Sons, L.L.C. | 2 | $48 |
| Teva Pharmaceuticals USA, Inc. | 2 | $47 |
| Otsuka America Pharmaceutical, Inc. | 2 | $41 |
| Alkermes, Inc. | 2 | $38 |
| Vanda Pharmaceuticals Inc. | 2 | $36 |
| Janssen Pharmaceuticals, Inc | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
Products named: VRAYLAR, CAPLYTA, COBENFY, REXULTI, ARISTADA, FANAPT, AUSTEDO XR, UZEDY.
Industry payments across MA — which companies pay providers there.
